142 related articles for article (PubMed ID: 37027571)
1. Gaps in Cystic Fibrosis Care Are Associated with Reduced Lung Function in the U.S. Cystic Fibrosis Foundation Patient Registry.
Sears EH; Hinton AC; Lopez-Pintado S; Lary CW; Zuckerman JB
Ann Am Thorac Soc; 2023 Sep; 20(9):1250-1257. PubMed ID: 37027571
[No Abstract] [Full Text] [Related]
2. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
3. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data.
Keogh RH; Szczesniak R; Taylor-Robinson D; Bilton D
J Cyst Fibros; 2018 Mar; 17(2):218-227. PubMed ID: 29311001
[TBL] [Abstract][Full Text] [Related]
4. Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation.
Sawicki GS; Van Brunt K; Booth J; Bailey E; Millar SJ; Konstan MW; Flume PA
J Cyst Fibros; 2022 Jan; 21(1):96-103. PubMed ID: 34289939
[TBL] [Abstract][Full Text] [Related]
5. Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene Mutation.
Sawicki GS; Konstan MW; McKone EF; Moss RB; Lubarsky B; Suthoff E; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan WJ; Duncan ME; Yang Y
Pulm Ther; 2022 Dec; 8(4):385-395. PubMed ID: 36319933
[TBL] [Abstract][Full Text] [Related]
6. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry.
MacKenzie T; Gifford AH; Sabadosa KA; Quinton HB; Knapp EA; Goss CH; Marshall BC
Ann Intern Med; 2014 Aug; 161(4):233-41. PubMed ID: 25133359
[TBL] [Abstract][Full Text] [Related]
7. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
8. Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis.
Konstan MW; VanDevanter DR; Sawicki GS; Pasta DJ; Foreman AJ; Neiman EA; Morgan WJ
Ann Am Thorac Soc; 2018 Apr; 15(4):485-493. PubMed ID: 29313709
[TBL] [Abstract][Full Text] [Related]
9. [Italian Cystic Fibrosis Registry (ICFR). Report 2017-2018].
Campagna G; Amato A; Majo F; Ferrari G; Quattrucci S; Padoan R; Floridia G; Salvatore D; Carnovale V; Puppo Fornaro G; Taruscio D; Salvatore M;
Epidemiol Prev; 2021; 45(3 Suppl 1):1-37. PubMed ID: 34132083
[TBL] [Abstract][Full Text] [Related]
10. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
12. The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry.
Knapp EA; Fink AK; Goss CH; Sewall A; Ostrenga J; Dowd C; Elbert A; Petren KM; Marshall BC
Ann Am Thorac Soc; 2016 Jul; 13(7):1173-9. PubMed ID: 27078236
[TBL] [Abstract][Full Text] [Related]
13. Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial.
Sagel SD; Khan U; Heltshe SL; Clancy JP; Borowitz D; Gelfond D; Donaldson SH; Moran A; Ratjen F; VanDalfsen JM; Rowe SM
Ann Am Thorac Soc; 2021 Jan; 18(1):75-83. PubMed ID: 32644818
[No Abstract] [Full Text] [Related]
14. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype.
De Boeck K; Weren M; Proesmans M; Kerem E
Pediatrics; 2005 Apr; 115(4):e463-9. PubMed ID: 15772171
[TBL] [Abstract][Full Text] [Related]
15. CFTR Genotype and Maximal Exercise Capacity in Cystic Fibrosis: A Cross-sectional Study.
Radtke T; Hebestreit H; Gallati S; Schneiderman JE; Braun J; Stevens D; Hulzebos EH; Takken T; Boas SR; Urquhart DS; Lands LC; Tejero S; Sovtic A; Dwyer T; Petrovic M; Harris RA; Karila C; Savi D; Usemann J; Mei-Zahav M; Hatziagorou E; Ratjen F; Kriemler S;
Ann Am Thorac Soc; 2018 Feb; 15(2):209-216. PubMed ID: 29140739
[TBL] [Abstract][Full Text] [Related]
16. [Italian Cystic Fibrosis Registry (ICFR). Report 2015-2016].
Giordani B; Amato A; Majo F; Ferrari G; Quattrucci S; Minicucci L; Padoan R; Floridia G; Salvatore D; Carnovale V; Puppo Fornaro G; Taruscio D; Salvatore M;
Epidemiol Prev; 2019; 43(4S1):1-36. PubMed ID: 31370382
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland.
Kirwan L; Fletcher G; Harrington M; Jeleniewska P; Zhou S; Casserly B; Gallagher CG; Greally P; Gunaratnam C; Herzig M; Linnane B; McElvaney NG; McKone EF; McNally P; Mullane D; Ní Chróinín M; O'Mahony M; Plant BJ; Jackson AD
Ann Am Thorac Soc; 2019 Feb; 16(2):209-216. PubMed ID: 30427731
[TBL] [Abstract][Full Text] [Related]
18. [Italian Cystic Fibrosis Registry (ICFR). Report 2019-2020].
Campagna G; Amato A; Majo F; Ferrari G; Quattrucci S; Padoan R; Floridia G; Salvatore D; Carnovale V; Puppo Fornaro G; Taruscio D; Salvatore M;
Epidemiol Prev; 2022; 46(4 Suppl 2):1-38. PubMed ID: 36102313
[TBL] [Abstract][Full Text] [Related]
19. Lung Function Decline in Cystic Fibrosis: Impact of Data Availability and Modeling Strategies on Clinical Interpretations.
Szczesniak R; Andrinopoulou ER; Su W; Afonso PM; Burgel PR; Cromwell E; Gecili E; Ghulam E; Goss CH; Mayer-Hamblett N; Keogh RH; Liou TG; Marshall B; Morgan WJ; Ostrenga JS; Pasta DJ; Stanojevic S; Wainwright C; Zhou GC; Fernandez G; Fink AK; Schechter MS
Ann Am Thorac Soc; 2023 Jul; 20(7):958-968. PubMed ID: 36884219
[No Abstract] [Full Text] [Related]
20. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor.
Rubin JL; O'Callaghan L; Pelligra C; Konstan MW; Ward A; Ishak JK; Chandler C; Liou TG
Ther Adv Respir Dis; 2019; 13():1753466618820186. PubMed ID: 30803355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
